risk factors identified for ROP [1] . Comorbidities, such as bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), and sepsis have been associated with ROP [2] [3] [4] . In recent years researchers have found that growth factors, such as insulin-like growth factor 1 and vascular endothelial growth factors (VEGF), have important influences in ROP development [5] .
ROP displays two phases of development (phases 1 and 2). Phase 1 is characterized by delayed retinal vessel growth, beginning from birth to weeks after birth. Phase 2 is characterized by neovascularization, beginning weeks to months after birth. ROP is classified by stage according to disease severity (ROP stages 0-5) and by zone according to the location of ROP in the retina (zones I to III) [6] .
The most severe form of rapidly progressing ROP is termed aggressive posterior ROP (APROP) [6] . APROP is a rare disease. In Sweden between 2008 and 2012, 5.2% of infants screened for ROP received treatment and of those treated 4.9% had APROP in zone 1 [7] . APROP is characterized by its posterior location (most commonly observed in zone 1, close to the optic nerve, or in posterior zone 2), prominent vascular activity (neovascularizations and plus disease; i.e. vessel dilation and tortuosity), and rapid, indistinct progression of neovascularization (ROP disease) [6] . APROP treatment may prevent blindness, but the treatment response and visual outcome have been poor, particularly when APROP occurs in zone 1 [8] .
Only a few studies have focused on the pathophysiology of APROP. Case reports and clinical experience suggest that APROP develops in infants with the worst health status; however, to our knowledge, only sepsis is identified as a significant risk factor for APROP [9] . Some studies suggest that low platelet counts/thrombocytopenia could be associated with APROP and that platelet transfusion might be a potential new ROP treatment strategy [10, 11] .
In Sweden, data on all infants screened for ROP are registered in SWEDROP, a national quality register with a 96% national coverage [7] . In this retrospective, nationbased, 1: 1 matched case-control study, we included infants registered in SWEDROP with APROP in zone 1 over a period of 5 years (2008-2012) . We determined the postnatal clinical course in preterm infants that developed APROP in zone 1 and in an age-and birth weight (BW)-matched control group, which developed only mild ROP (no worse than stage 2). We aimed to investigate the postnatal characteristics in APROP development.
Methods

Ethical Considerations
The study protocol was approved by the Regional Ethics Review Board in Uppsala, Sweden.
Study Population
The present study included infants registered in SWEDROP with APROP in zone 1, born between January 1, 2008 and December 31, 2012 (n = 9). We performed a retrospective review of medical records from birth to the first ROP treatment. Data on gestational age (GA) and BW were retrieved, as well as the following data on neonatal morbidities: BPD, NEC (medical or surgical interventions, and the number of treatment episodes), IVH, and sepsis (defined as a positive blood culture). We recorded all available data on laboratory measurements of platelet counts and C-reactive protein (CRP) and platelet transfusions. We retrieved data from SWEDROP on ROP status, development, and treatment interventions.
Characteristic
Cases (n = 9) Controls (n = Values are presented as the median (min., max.) or n (%). BWSDS = BW standard deviation score; n.s. = nonsignificant. 1 Calculated with the Scandinavian gender-specific growth reference produced by Marsál et al. [22] . 2 Mann-Whitney U test. 3 Fischer's exact test. Each control case was individually matched to an APROP case for BW (within 100 g) and GA (within 1 week). Controls were confirmed to have only mild ROP, no worse than ROP stage 2. For each control case, we retrospectively reviewed the medical records for data equivalent to those retrieved for the APROP cases, up to the postmenstrual age (PMA) when the matched APROP infant received the first ROP treatment.
Neonatal Morbidities and Postnatal Clinical Course
BPD was defined as the need for continuous supplemental oxygen at 36 weeks PMA [12] . NEC was defined as stage 2b or more [13] . IVH included all grades of IVH. Sepsis was defined as a positive blood culture. To describe all events of an infectious character we implemented the term 'infectious episodes', defined as any sepsis, CRP ≥ 10 mg/l, or other clinical signs of infection that required antibiotic treatment.
Platelet Count, CRP and Platelet Transfusions
All available values for the platelet count and CRP were retrieved from the infants' medical records. When several values were available per day, the lowest platelet count value and the highest CRP value were recorded for that day. National recommendations defined neonatal thrombocytopenia as a platelet count <100 × 10 9 /l. Data concerning platelet transfusions (volume in milliliters per day) were retrieved. 
ROP Examinations
All infants were examined according to the established Swedish ROP screening guidelines previously described by Holmström et al. [7] . APROP was diagnosed according the international classification [6] , which described it as follows: 'The characteristic features of this type of ROP are its posterior location, prominence of plus disease, and the ill-defined nature of the retinopathy.'
Statistical Analysis
All statistical analyses, calculations of medians and percentages, and the generation of graphics were carried out with IBM SPSS Statistics 20 for Microsoft Windows (IBM, Armonk, N.Y., USA). The Fisher's exact test, χ 2 and Mann-Whitney U tests were used to explore the relationships between variables.
Results
Birth Characteristics
The birth characteristics of the 9 APROP cases and their 9 matched controls are shown in table 1 .
Neonatal Morbidities and Postnatal Clinical Course
The neonatal morbidities and postnatal clinical course of the 9 APROP cases and their 9 matched controls are shown in table 1 . NEC and sepsis occurred significantly more frequently among APROP cases than among controls (p < 0.01 and p < 0.01, respectively). All APROP cases had at least two postnatal infectious episodes before the first ROP treatment. Graphic representation of the 9 infants that developed AP-ROP (cases) and the 9 age-and BW-matched infants that developed only mild ROP (controls). The horizontal line represents the transition from phase 1 to phase 2 of ROP development. The large gray arrow shows that the clinical signs differed significantly between the two groups during phase 2. The small arrows represent infants with one or more infectious episode events (black arrows) or infants with one or more events of thrombocytopenia (white arrows).
thrombocytopenia that lasted for several weeks ( fig. 1 ). Of the 9 controls, 6 developed thrombocytopenia within the first month of life. Only 1 control had an additional period of thrombocytopenia at or after a PMA of 31 weeks. Figure 2 presents a schematic diagram of these results. Days of thrombocytopenia (p < 0.001) and days of platelet transfusion (p < 0.001) occurred significantly more frequently among APROP cases. Median platelet counts (p < 0.001) were significantly lower and median platelet volumes (ml/day) transfused (p < 0.01; table 2 ) significantly higher in APROP cases. In table 3 the timing of platelet transfusions in APROP cases are presented. APROP case 2 received numerous platelet transfusions in a total volume of 195 ml, but a stable increase in platelet count was not achieved. Of the 9 controls, 2 received a platelet transfusion during their first week of life.
ROP Development and ROP Treatment
In table 3 , the timing and characteristics at the first sign of ROP and ROP treatment interventions in APROP cases are presented. ROP treatment was provided for all APROP cases at a median PMA of 34 weeks and 2 days (range 32 + 2 to 36 + 5). The median number of treatments for APROP was 3 treatment sessions per eye (range 1-5). APROP cases often received a combination of treatment interventions in the same session. Among the 9 control cases, 1 had no ROP, 3 had ROP stage 1, and 2 had ROP stage 2. Discussion APROP is a rare disease, but it generally has a devastating visual outcome, particularly when it appears in zone 1. In this retrospective, nation-based, 1: 1 case-control study, we found that multiple infectious episodes and thrombocytopenia in both phases of ROP were associated with APROP development. To the best of our knowledge, this study was the first to suggest this 'multiple-hit pattern' in APROP development. All infants that developed AP-ROP (9/9 cases) had at least one infectious episode and thrombocytopenia within the first month of life in phase 1. Then, within weeks to months after birth, the majority of APROP cases had a second infectious episode and an additional period of thrombocytopenia in phase 2. In contrast, infants that developed only mild ROP (controls) had infectious episodes and thrombocytopenia less frequently than infants with APROP, particularly in phase 2.
In agreement with Borroni et al. [9] , sepsis was significantly more frequent in APROP cases in our study. However, to describe all events of an infectious character, we implemented the term 'infectious episodes', which included sepsis and any conditions that caused an increase in CRP ( ≥ 10 mg/l) or clinical signs of infection that required antibiotic treatment. All APROP cases displayed at least two postnatal infectious episodes before ROP treatment in both phases of ROP.
Consistent with thrombocytopenia, APROP cases displayed a median platelet count that was significantly lower than that of controls, supporting the findings of Vinekar et al. [10] and Jensen et al. [11] . Days of platelet transfusion were significantly more frequent and the median volume platelets transfused was significantly higher in APROP cases compared to the controls. These results could be interpreted as multiple platelet transfusions being a significant risk factor for APROP. However, APROP cases showed a persistent low platelet count despite frequent transfusions and we therefore hypothesize that thrombocytopenia per se is the risk factor for AP-ROP. Vinekar et al. [10] described an infant with APROP and thrombocytopenia that showed spontaneous AP-ROP regression after multiple platelet transfusions and an increase in platelet count, which suggested a potential new ROP treatment strategy if appropriately timed platelet transfusion is effective. Thrombocytopenia is common in neonates, particularly those born extremely preterm with a low BW [14] . A ≥ 30% drop in platelet counts also without reaching thrombocytopenia as well as thrombocytopenia per se have been correlated and suggested to predict the onset of morbidities and mortality [15] . It is possible that thrombocytopenia alone is associated with APROP, because sepsis can cause low platelet counts [16] . The exact relationship between low platelet counts and ROP remains unclear. Several studies have indicated that platelets are major regulators of angiogenic regulatory proteins, such as VEGF. Platelets store, transport, and deliver VEGF [17] . Increased local and systemic VEGF levels have been detected in the proliferative phase of ROP and primarily at the first detection of ROP [18] . However, it is not clear whether thrombocytopenia disturbs the retinal VEGF balance and how these disturbances might affect each phase of ROP.
In the present study, all APROP cases were affected by one or several comorbidities, including BPD, NEC, and/ or IVH, which are well known to be associated with ROP [2, 3] . However, only NEC occurred significantly more frequently in APROP cases than in controls. ROP screening is often difficult, especially for infants developing NEC due to their extremely fragile state of health. However, since infants with NEC are at the highest risk of severe ROP development, we want to emphasize the importance of following screening guidelines for these infants in particular, as suggested previously by van Sorge et al. [19] . The exact relationship between NEC and ROP is unclear. Perplexingly, low oxygen saturation has been found to be a risk factor for NEC [20] .
All APROP cases required several ROP treatment sessions, except for 2 infants who were treated with intraocular injections of anti-VEGF antibody in an initial treatment. Anti-VEGF treatment has been suggested as the treatment of choice for ROP in zone 1 [21] .
The primary strength of our study was that we included a nation-based cohort due to the availability of data in SWEDROP, which tracks infants with complete records during the neonatal period. Another strength was the availability of high-frequency platelet counts in both APROP cases and controls. Although this study was retrospective, the platelet counts were recorded prospectively. Our findings have provided a basis for future, prospective studies, which could investigate the roles of platelets and infectious episodes in the pathogenesis of ROP and APROP.
In conclusion, this study showed that APROP in zone 1 was associated with a 'multi-hit' pattern of pathogenesis. This pattern included infectious episodes and thrombocytopenia in both phases of ROP. Hence, infants with multiple episodes of infection and thrombocytopenia should be given special attention in ROP screening.
